Pharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-saving
MetadataShow full item record
CitationWu, Ann Chen, Charlene Gay, Melisa D Rett, Natasha Stout, Scott T Weiss, and Anne L Fuhlbrigge. 2015. “Pharmacogenomic Test That Predicts Response to Inhaled Corticosteroids in Adults with Asthma Likely to Be Cost-Saving.” Pharmacogenomics 16 (6) (April): 591–600. doi:10.2217/pgs.15.28.
AbstractAim: To identify the clinical and economic circumstances under which a pharmacogenomic test that predicts response to inhaled corticosteroids might be a cost-effective option for individuals with asthma.
Materials & methods: We synthesized published data on clinical and economic outcomes to project 10-year costs, quality-adjusted life-years and cost–effectiveness of pharmacogenomic testing for inhaled corticosteroid response. We assumed the pharmacogenomic test cost was $500 with a sensitivity and specificity of 84 and 98%, respectively. These were varied in sensitivity analyses.
Results: Both strategies, pharmacogenomic testing for inhaled corticosteroid response and no testing conferred 7.1 quality-adjusted life-years. Compared with no testing, pharmacogenomic testing costs less.
Conclusion: Pharmacogenomic testing for asthma is cost-saving and noninferior in improving health.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:27015682
- SPH Scholarly Articles